News
Subscribe to our news & insights

3 February 2026
BDA advises Salica on sale of Bluewater Bio to Verdane and Scott Capital…

5 January 2026
BDA advises Khandelwal Labs on sale of non-oncology branded generics business…

31 December 2025
BDA advises on acquisition of Encora by Coforge

23 December 2025
BDA advises Wärtsilä on sale of Gas Solutions business to Mutares
Insights
4 February 2026
BDA promotions 2026
As we begin 2026 with a record book of business, BDA Partners is pleased…
2 January 2026
BDA celebrates 30 years of global investment banking
BDA Partners will celebrate its 30th year of doing business in 2026. …
12 December 2025
BDA named The Outstanding M&A Advisor in Vietnam
At the recent Vietnam M&A Forum in Ho Chi Minh City, BDA was recognised…
About us
We are a premium provider of advice to sophisticated clients globally, with 30 years’ experience and a strong track record for advising corporates and financial sponsors on cross-border M&A, capital raising, secondary transactions, and financial restructuring.
As the leading sellside investment banking advisor, we specialize in cross-border transactions and have over 120 bankers throughout our nine offices located across North America, Europe and Asia.
At a glance
#1
Cross-border Asian sellside M&A advisor†
1996
Founded and led since then by the same senior team
75%
Of transactions are cross-border
120+
Bankers collaborating seamlessly across three continents
Recent transactions

sold

to

via Aquavest
2026

divested non-oncology pharma business division to


2026

Advent, Warburg Pincus and minority shareholders have agreed to sell

to

2025

agreed to sell its Gas Solutions business to


2025

raised capital from


2025

divested majority stake in


2025

agreed to sell majority stake to


2025

has been acquired by


2025

divested

to

2025
†Private companies headquartered in China, India, Japan, Korea or Southeast Asia; Control transactions up to US$1bn enterprise value, 2016-2024 Source: Dealogic










